Evidence map›Paper›PMID 35968372›Full record

ArticleFrontiers in neuroscience2022

Identification of BAG5 as a Potential Biomarker for Parkinson's Disease Patients With R492X

Yu Fu, Yongkang Chen, Haiyan Tian, Han Liu, Dan Qi, Erxi Wu, Xuejing Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yu FuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yongkang ChenDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haiyan TianDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Han LiuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dan QiNeuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, TX, United States.
Erxi WuNeuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, TX, United States.
Xuejing WangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNBaylor Scott & White Health · USTexas A&M Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a degenerative, progressive nervous system disorder with an unknown cause.

Indexed as

Bcl2-associated athanogene 5Parkinson’s diseaseR492X PINK1 mutation degradationskinubiquitination

Identifiers

PMID35968372
PMCPMC9363588
OpenAlexW4288033610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.